- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute | Strategic Alliance Partners
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Latest from Dana-Farber Cancer Institute
Dr Brown on the Potential for Pirtobrutinib to Address Treatment Discontinuation in CLL
April 09, 2024
Video
Jennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia.
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer
April 08, 2024
Video
Rebecca L. Porter, MD, PhD, discusses the evaluation of mirvetuximab soravtansine plus pembrolizumab in FRα-positive, pMMR/MSS endometrial cancer.
Neuro-Inclusive Oncology Care and Empowerment Program
April 08, 2024
Article
Dana-Farber details how their Neuro-Inclusive Oncology Care and Empowerment program was developed to help physicians and other providers treat cancer in patients who have intellectual and/or developmental disabilities.
Dr Xu on Ongoing Biomarker Research in Metastatic RCC
April 05, 2024
Video
Wenxin (Vincent) Xu, MD, discusses ongoing efforts to identify new biomarkers in metastatic renal cell carcinoma.
Scott Armstrong Named Senior Vice President for Drug Discovery and Chief Research Strategy Officer at Dana-Farber
April 02, 2024
Article
Scott Armstrong, MD, PhD, has been named senior vice president for drug discovery and chief research strategy officer at Dana-Farber Cancer Institute.
Ongoing Trials Aim to Build on Systemic Therapy Combinations in Advanced RCC
April 01, 2024
Article
Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.
Establishing Biomarkers Is Key to Driving Personalized Systemic Treatment Choices in Advanced RCC
March 30, 2024
Article
Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.
Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
March 28, 2024
Podcast
Dr Wagner discusses unmet needs for patients with PEComa, ongoing research to address these gaps, and findings from the AMPECT trial.
Supportive Care and Medication Access in GvHD
March 27, 2024
Video
Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.
Dr Xu on Ongoing Research Initiatives in ccRCC
March 27, 2024
Video
Wenxin (Vincent) Xu, MD, highlights research in renal cell carcinoma, spotlighting developments and updates in patients with non-clear cell disease.
Dr Brown on the Implications of Genomic Data for Pirtobrutinib Use in CLL
March 25, 2024
Video
Jennifer R. Brown, MD, PhD, discusses results from a genomic analysis of responses with pirtobrutinib in patients with chronic lymphocytic leukemia.
Taplin Tackles Equitable Treatment in Prostate Cancer
March 24, 2024
Article
Mary-Ellen Taplin, MD, discusses ways to mitigate health care disparities in the treatment of patients with prostate cancer.
Dr Xu on Treatment Decision-Making in RCC
March 22, 2024
Video
Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.
Dr D’Amico on Advancements in High-Risk Prostate Cancer Diagnosis and Management
March 22, 2024
Video
Anthony V. D'Amico, MD, PhD, on the advancements in high-risk prostate cancer diagnosis and management
Remote Online Genetic Education Programs Can Spur Testing for Inherited Susceptibility to Cancer, Study Suggests
March 21, 2024
Article
In the GENERATE study, 90% of those who viewed an online genetic education program chose to be tested for inherited predisposition to pancreatic cancer.
Therapies in Development for Chronic GvHD
March 20, 2024
Video
Drs Cutler and Safah look to the future of chronic GvHD treatment and discuss ongoing research, highlighting studies investigating axatilimab and abatacept.
Approved Therapies for Steroid-Refractory Chronic GvHD
March 20, 2024
Video
Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.
Dr Taplin on Health Care Inequities in Prostate Cancer Treatment
March 20, 2024
Video
Mary-Ellen Taplin, MD, discusses strategies to mitigate health care inequities in prostate cancer.
Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice
March 18, 2024
Article
The Third Transatlantic Exchange in Oncology Conference will focus on liquid biopsy as an emerging approach in precision cancer medicine.